
Group 1 - Spartan Capital Securities, LLC successfully completed a $3,788,000 private placement for Lipella Pharmaceuticals Inc. [1][2] - The proceeds will support Lipella's mission to develop innovative therapies for unmet medical needs and fund general corporate purposes [2] - Jonathan Kaufman, CEO of Lipella, is focused on advancing the company's clinical pipeline and transformative treatments [2] Group 2 - John Lowry, CEO of Spartan Capital, expressed honor in serving as the sole placement agent and highlighted Lipella's commitment to medical innovation [3] - The transaction reflects the strength of Lipella's vision and Spartan Capital's dedication to impactful investment opportunities [3] - Legal counsel for the transaction included Sichenzia Ross Ference Carmel LLP for the placement agent and Sullivan & Worcester LLP for Lipella [3] Group 3 - Further details on the transaction will be available in Lipella's Form 8-K, to be filed with the U.S. Securities and Exchange Commission [4] - The common shares and related warrants have not been registered under the Securities Act of 1933, limiting their sale until registration or exemption [5] - This press release does not constitute an offer to sell or solicit offers to buy the securities [6]